Zoetis (ZTS) to Release Earnings on Thursday

Zoetis (NYSE:ZTSGet Rating) will post its quarterly earnings results before the market opens on Thursday, May 5th. Analysts expect Zoetis to post earnings of $1.22 per share for the quarter. Zoetis has set its FY 2022 guidance at $5.090-$5.190 EPS and its FY22 guidance at $5.09-$5.19 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Zoetis (NYSE:ZTSGet Rating) last posted its quarterly earnings data on Tuesday, February 15th. The company reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.04. The business had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zoetis had a return on equity of 50.71% and a net margin of 26.20%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.91 earnings per share. On average, analysts expect Zoetis to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

ZTS stock opened at $178.47 on Thursday. The company has a market capitalization of $84.20 billion, a P/E ratio of 41.80, a PEG ratio of 3.13 and a beta of 0.77. Zoetis has a twelve month low of $165.22 and a twelve month high of $249.27. The business has a 50 day simple moving average of $189.79 and a 200-day simple moving average of $206.35. The company has a current ratio of 3.86, a quick ratio of 2.79 and a debt-to-equity ratio of 1.45.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 1st. Investors of record on Thursday, April 21st will be issued a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a dividend yield of 0.73%. The ex-dividend date is Wednesday, April 20th. Zoetis’s dividend payout ratio is presently 30.45%.

ZTS has been the subject of several research analyst reports. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Citigroup dropped their price target on Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research report on Wednesday, March 9th. Finally, Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating and set a $242.00 price target for the company. in a research report on Saturday, January 8th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $224.78.

In related news, EVP Glenn David sold 32,390 shares of the firm’s stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $189.87, for a total transaction of $6,149,889.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roman Trawicki sold 6,000 shares of the stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $188.15, for a total transaction of $1,128,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,455 shares of company stock worth $9,607,544. 0.17% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of ZTS. Morgan Stanley increased its stake in shares of Zoetis by 4.6% during the second quarter. Morgan Stanley now owns 7,561,487 shares of the company’s stock valued at $1,409,158,000 after acquiring an additional 333,952 shares during the period. Barclays PLC increased its stake in shares of Zoetis by 23.1% in the fourth quarter. Barclays PLC now owns 1,115,154 shares of the company’s stock worth $272,130,000 after acquiring an additional 209,028 shares during the last quarter. Comerica Bank increased its position in Zoetis by 88.5% during the third quarter. Comerica Bank now owns 414,953 shares of the company’s stock worth $86,066,000 after buying an additional 194,874 shares during the last quarter. NewEdge Advisors LLC increased its position in Zoetis by 100.5% during the fourth quarter. NewEdge Advisors LLC now owns 16,769 shares of the company’s stock worth $4,093,000 after buying an additional 8,407 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich increased its position in Zoetis by 31.0% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 34,345 shares of the company’s stock worth $8,381,000 after buying an additional 8,118 shares during the last quarter. Hedge funds and other institutional investors own 90.36% of the company’s stock.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Earnings History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.